Sepracor, MedPointe To End Astelin Co-Promotion Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies will continue to detail the product until June 30, then Sepracor will be responsible for sample coverage until the end of the year. Sepracor plans to focus sales efforts on in-house products.
You may also be interested in...
Swedish Specialty Pharma Meda Acquires MedPointe In $800 Million Transaction
Meda also acquires MedPointe’s 500-strong U.S. sales force in the deal.
Swedish Specialty Pharma Meda Acquires MedPointe In $800 Million Transaction
Meda also acquires MedPointe’s 500-strong U.S. sales force in the deal.
MedPointe Pumps Up The Volume On Astelin Marketing Campaign
Firm’s new marketing program for the nasal spray includes a direct-to-consumer advertising campaign and an increase in sales reps.